Safety of corticosteroids in the treatment of acute respiratory disease in children: a systematic review and meta-analysis.
Corticosteroids
acute respiratory disease
meta-analysis
Journal
Translational pediatrics
ISSN: 2224-4344
Titre abrégé: Transl Pediatr
Pays: China
ID NLM: 101649179
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
19
11
2021
accepted:
30
12
2021
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
ppublish
Résumé
Oral corticosteroids are often used to treat acute asthma or asthma caused by respiratory tract infection in adult patients, but the effect of oral corticosteroids in young children is still controversial. We conducted a meta-analysis of controlled clinical studies to examine the effect of oral corticosteroids in children with respiratory diseases. Embase, PubMed, Web of Science, Ovid, ClinicalTrials.org from January 2000 to August 2021 were searched for randomized control trials related to the treatment of pediatric respiratory diseases with corticosteroid drugs using the keywords "corticosteroids" and "acute respiratory diseases". After screening the articles, Revman 5.4 software was used for the analysis. A total of 8 articles (comprising 2,327 patients, 4 kinds of corticosteroids, and 3 types of pediatric respiratory disease) were included in the meta-analysis. The results showed that the length of hospital stay of patients in the experimental group treated with corticosteroids was shorter than that of patients in the control group [mean difference =-2.03, 95% confidence interval (CI): -2.91, -1.14; P<0.00001]. Further, the number and proportion of uncured patients after 3 days of treatment were lower in the experimental group than the control group [odds ratio (OR) =0.55, 95% CI: 0.42, 0.72; P<0.00001]. There were no differences in relation to adverse reactions (OR =0.57, 95% CI: 0.31, 1.07; P=0.08), and the readmission rate between the experimental and control groups (OR =0.94, 95% CI: 0.66, 1.34; P=0.75). Corticosteroid use in the treatment of respiratory diseases in children can significantly shorten hospitalization time and increase the cure rate without increasing adverse reactions.
Sections du résumé
Background
UNASSIGNED
Oral corticosteroids are often used to treat acute asthma or asthma caused by respiratory tract infection in adult patients, but the effect of oral corticosteroids in young children is still controversial. We conducted a meta-analysis of controlled clinical studies to examine the effect of oral corticosteroids in children with respiratory diseases.
Methods
UNASSIGNED
Embase, PubMed, Web of Science, Ovid, ClinicalTrials.org from January 2000 to August 2021 were searched for randomized control trials related to the treatment of pediatric respiratory diseases with corticosteroid drugs using the keywords "corticosteroids" and "acute respiratory diseases". After screening the articles, Revman 5.4 software was used for the analysis.
Results
UNASSIGNED
A total of 8 articles (comprising 2,327 patients, 4 kinds of corticosteroids, and 3 types of pediatric respiratory disease) were included in the meta-analysis. The results showed that the length of hospital stay of patients in the experimental group treated with corticosteroids was shorter than that of patients in the control group [mean difference =-2.03, 95% confidence interval (CI): -2.91, -1.14; P<0.00001]. Further, the number and proportion of uncured patients after 3 days of treatment were lower in the experimental group than the control group [odds ratio (OR) =0.55, 95% CI: 0.42, 0.72; P<0.00001]. There were no differences in relation to adverse reactions (OR =0.57, 95% CI: 0.31, 1.07; P=0.08), and the readmission rate between the experimental and control groups (OR =0.94, 95% CI: 0.66, 1.34; P=0.75).
Discussion
UNASSIGNED
Corticosteroid use in the treatment of respiratory diseases in children can significantly shorten hospitalization time and increase the cure rate without increasing adverse reactions.
Identifiants
pubmed: 35282016
doi: 10.21037/tp-21-577
pii: tp-11-02-194
pmc: PMC8905102
doi:
Types de publication
Journal Article
Langues
eng
Pagination
194-203Informations de copyright
2022 Translational Pediatrics. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-21-577/coif). The authors have no conflicts of interest to declare.
Références
Trials. 2014 Apr 27;15:147
pubmed: 24767719
Acta Paediatr. 2005 Jul;94(7):866-71
pubmed: 16188807
J Allergy Clin Immunol. 1977 Apr;59(4):298-308
pubmed: 321503
Crit Care Med. 2011 Jul;39(7):1779-83
pubmed: 21460709
Pediatr Infect Dis J. 2003 Aug;22(8):721-6
pubmed: 12913774
BMJ Open. 2019 Aug 1;9(8):e028511
pubmed: 31375615
Environ Res. 2020 Sep;188:109619
pubmed: 32531523
Pol Arch Intern Med. 2020 Apr 30;130(4):276-286
pubmed: 32186831
Pediatr Allergy Immunol. 2007 Jun;18(4):326-34
pubmed: 17584312
Crit Care Med. 2020 Dec;48(12):e1368-e1369
pubmed: 33255135
Pediatr Allergy Immunol. 2006 May;17 Suppl 17:14-20
pubmed: 16573704
Arch Dis Child. 2021 Apr;106(4):339-344
pubmed: 33067310
Pediatr Blood Cancer. 2008 May;50(5):1006-12
pubmed: 17849474
J Pediatr. 2003 Dec;143(6):725-30
pubmed: 14657816
Arch Dis Child. 2000 Feb;82(2):126-30
pubmed: 10648365
Pediatr Pulmonol. 2013 Feb;48(2):168-75
pubmed: 22588852
Indian J Pediatr. 2015 Jul;82(7):629-36
pubmed: 25257964
Lancet. 2003 Nov 1;362(9394):1433-8
pubmed: 14602435
N Engl J Med. 2009 Jan 22;360(4):329-38
pubmed: 19164186
Pediatrics. 2000 Apr;105(4):E44
pubmed: 10742365
Int J Pediatr Otorhinolaryngol. 2006 Mar;70(3):445-52
pubmed: 16140398
Arch Dis Child. 2016 Aug;101(8):752-8
pubmed: 26768831
Lancet Respir Med. 2018 Feb;6(2):97-106
pubmed: 29373235